A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis

Trial Profile

A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs EYS 606 (Primary)
  • Indications Uveitis
  • Focus Adverse reactions; First in man
  • Sponsors Eyevensys
  • Most Recent Events

    • 13 Sep 2017 EYS606 has been granted an Orphan drug designation by the European Medicines Agency (EMA) for the treatment of NIU, according to an Eyevensys media release.
    • 09 May 2017 Professor Antoine Brezin is the principal investigator of the trial, according to an Eyevensys media release,
    • 09 May 2017 According to an Eyevensys media release, the first patient has been successfully treated in this trial and initial trial results are expected in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top